Tchelebi LT, Lehrer EJ, Trifiletti DM, et al. - Researchers compared stereotactic body radiation therapy (SBRT) vs conventionally fractionated radiation therapy with concurrent chemotherapy (CFRT), in terms of efficacy and safety for the definitive treatment of locally advanced pancreatic cancer (LAPC). Efficacy was defined by 2-year overall survival (OS) and was considered as the primary outcome measure, and the incidence of any grade 3/4 toxicity and 1-year OS were assessed as secondary outcomes. The eligible studies were selected by applying a PICOS/PRISMA/MOOSE selection protocol. Of initially screened 470 studies, 9 evaluated SBRT and 11 studies evaluated CFRT. The median dose for SBRT was 30 Gy, the most common regimen was 30 Gy/5 fractions. Doses ranged from 45 to 54 Gy in 1.8- to 2.0-Gy fractions for CFRT, with the majority of studies delivering 50.4 Gy in 28 fractions with concurrent gemcitabine. A modest improvement in 2-year OS may be achieved with SBRT, with reduced rates of acute grade 3/4 toxicity and no alteration in 1-year-OS or late toxicity among patients with LAPC.